Abstract
Graft-versus-host disease (GVHD) is a complicated disease whose treatment requires an equally multifaceted approach. Recipient conditioning, donor T cell activation, and end stage effectors all may be potential targets for treatment. Many drugs used in the past are returning to the forefront for investigation. Some of the newer nucleoside analogs that are in various stages of development, such as fludarabine and pentostatin, are showing promising activity in GVHD.
Similar content being viewed by others
References
Hill GR, Cooke KR, Teshima T, Crawford JM, Keith JC Jr, Brinson YS, Bungard D, Ferrara JL . Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation J Clin Invest 1998 102: 115–123
Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R . Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756–763
Porter DL, Connors JM, Van Deerlin VMD, Duffy KM, McGarigle C, Saidman SL, Leonard DGB, Antin JH . Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies J Clin Oncol 1999 17: 1239–1243
Schlegel PG, Aharoni R, Chen Y, Chen J, Teitelbaum D, Arnon R, Sela M, Chao NJ . A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine grant-versus-host disease in vivo Proc Natl Acad Sci USA 1996 93: 5061–5066
Anasetti C, Hansen JA, Waldmann TA, Appelbaum FR, Davis J, Deeg HJ, Doney K, Martin PJ, Nash R, Storb R et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor Blood 1994 84: 1320–1327
Or R, Weiss L, Teiman S, Polliack A . Fludarabine monophosphate reduces the incidence and severity of graft-versus-host disease in a murine model of bone marrow transplantation (letter) Blood 1997 90: 471
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vogelsang, G. Advances in the treatment of graft-versus-host disease. Leukemia 14, 509–510 (2000). https://doi.org/10.1038/sj.leu.2401687
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401687
- Springer Nature Limited